ICER releases new tools to facilitate use of its reports
Influential US pricing watchdog the Institute for Clinical and Economic Review (ICER) has announced the development of two new tools for payers, pharma firms and others to access its cost-effectiveness analyses.
The new decision-support tools – the ICER Evidence Compendium and the ICER Interactive Modeler – will be subscription-based products intended to make past and present ICER work easier to search and analyze.
Commenting on the new tools, President Steven Pearson said: “With these advancements, the US health system will be able to more effectively integrate and systematize ICER assessments, so that evidence can be used in a more transparent way to better align a treatment’s price to its ability to improve patients’ lives.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze